I can't stop thinking about neurodisease patients and families struggling without answers. You may already know this, but neurological diseases are common and nearly impossible to treat with modern tools. This is for one, singular reason: we have no way of measuring therapeutic success or failure. No way of knowing when therapies work or don't work. No feedback loop. Today's best solution is to watch for long-term changes in patient behavior, which is subjective, inconsistent, and subtle.

Tracing this cause back to its root, we find that the problem is with modern brain imaging. Today's imaging is deeply limited: we know when neurons are present or absent... and that's pretty much it! It’s like trying to find a car crash with a map that shows roads but not traffic flow. MRI and PET scans show the brain’s roads—its neurons—but not how signals travel between them. That’s when I realized the problem was what we weren’t seeing—the brain’s traffic.

Next, I wondered if this limitation could somehow be part of the solution... If we can only measure consequence, could we look at behavioral consequences within the brain? How one neuron is supposed to talk to another neuron, and where communication breaks down? This is the rationale behind a new kind of imaging: Evoked Potential Tomography (EPT). Over the past 5 years, I've developed EPT specifically to measure inter-neuron behaviors that: accurately differentiate diseases, objectively measure patient improvement/decline, and increase our fundamental understanding of brain function.

To solve this imaging problem, I had to rethink how we see the brain. EPT rests on three ideas that opened my eyes:

• First, picture your brain as a vast highway system where every neuron is a road with a specific job. Symptoms, like memory loss or tremors, come from traffic jams on specific roads—patterns of disrupted signals between neurons, whether caused by injury or disease. Mapping these traffic jams offers real hope for patients seeking clarity. EPT focuses on each neuron's unique role, which is novel.
• Second, let's send a series of individual signals, e.g. single cars, down each neuron’s road. We can watch how each one travels—whether speeding along or jamming. In testing many neurons this way, we pinpoint all the traffic jams in a patient’s brain, showing exactly where signals break down. Unlike methods that only capture broad traffic patterns, EPT zooms in on individual roads, revealing precise neuron-to-neuron interactions.
• Finally, these test signals paint a detailed map of the brain’s highways, showing where traffic flows smoothly or stalls. This map uncovers the traffic jams which fully explain the symptoms, diagnosis, and guides doctors to the best treatment for the patient.

So, what is Evoked Potential Tomography? EPT is the concept of evoking specific signals in the brain to compare how individual neurons work together between patients with different conditions. Unlike other methods that only measure broad brain activity, EPT pinpoints precise neuron-to-neuron connections with unmatched clarity. Critically, EPT is a new imaging technique with significantly higher resolution than existing imaging. Instead of measuring presence of neurons, we can finally measure performance.

After 5 years, I've now run multiple clinical studies to test the EPT hypothesis and evaluate its clinical utility, with results that matched MRI and PET scans with unprecedented detail. When we think of modern brain imaging, MRI and PET rise to the top as the highest resolution techniques. Well, EPT combined with artificial intelligence techniques is fully capable of independently reproducing MRI and PET DICOM images. In other words, equivalency. In addition, EPT can predict patient performance across a wide variety of cognitive/behavioral exams. Finally, EPT can separate patients who otherwise appear similar in MRI, PET, and behavior, by revealing who has greater disease progression and their rate of progression over time.

These results mean more than data—they’re hope for patients who’ve felt unheard and clarity for doctors seeking answers. This is a monumental breakthrough for neuroscience, neurology, and general brain health! For the first time, we finally have direct biomarkers of neurodisease progression. Yes, this is a bold claim, but the science is sound, the results are robust, and you can read more on my company website, Vistim Labs: Publications.